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Abstract
Rationale: Serum chitinases may be novel biomarkers of airway
inﬂammation and remodeling, but less is known about factors
regulating their levels.
Objectives: To examine serum chitotriosidase activity and YKL-40
levels in patients with asthma and chronic obstructive pulmonary
disease (COPD) and evaluate clinically relevant factors that may affect
chitinase levels, including genetic variability, corticosteroid treatment,
disease exacerbations, and allergen exposure.
Methods: Serumchitotriosidase (CHIT1) activity andYKL-40 (CHI3L1)
levels, as well as the CHIT1 rs3831317 and CHI3L1 rs4950928 genotypes,
were examined in subsets of patients with mild to moderate asthma
(n = 76), severe asthma (n = 93), and COPD (n= 64) taking part in the
European multicenter BIOAIR (Longitudinal Assessment of Clinical
Course and Biomarkers in Severe Chronic Airway Disease) study. Blood
wasobtainedatbaseline,beforeandaftera2-weekoral steroid intervention,
up to six times during a 1-year period, and during exacerbations. Baseline
chitinase levelswerealsomeasured in72healthycontrol subjects.Theeffect
of allergen inhalationonbloodandsputumYKL-40 levelswasmeasured in
two separate groups of patients with mild atopic asthma; one group
underwent repeated low-dose allergen challenge (n = 15), and the other
underwent high-dose allergen challenge (n = 16).
Measurements andMain Results: Serum chitotriosidase and YKL-
40 were signiﬁcantly elevated in patients with asthma and those with
COPD compared with healthy control subjects. Genotype and age
stronglyaffectedbothYKL-40andchitotriosidaseactivity,butassociations
withdisease remained following adjustment for these factors.Correlations
wereobservedwith lung functionbutnotwithotherbiomarkers, including
exhalednitricoxide, bloodeosinophils, periostin, andIgE.Generally, acute
exacerbations, allergen-induced airway obstruction, and corticosteroid
treatment did not affect circulating chitinase levels.
Conclusions:YKL-40 and chitotriosidase are increased in asthma and
more so in COPD. The data in the present study support these
substances as being relatively steroid-insensitive, non–T-helper cell type
2–type biomarkers distinctly related to chronic inﬂammatory disease
processes.
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To realize the concept of precision medicine
in patients with severe airway inﬂammation,
who are notoriously difﬁcult to treat, there is
a great need for novel biomarkers of this
disease. A relatively unexpected group of
proteins has been proposed to show
potential for this purpose—the chitinases.
Chitin is an abundant, tough structural
polysaccharide used by a variety of
organisms, including insects, crustaceans,
parasites, fungi, and bacteria, to protect
against external threats (1). Although in
humans chitin seems absent, enzymes
capable of its degradation are expressed.
The chitinase family includes the true
chitinases—acidic mammalian chitinase
(AMCase) and chitotriosidase—as well as
the structurally related chitinase-like
protein YKL-40, which lacks enzymatic
activity (2). In recent years, these proteins
have been linked to airway inﬂammation
(2). Although AMCase has been associated
with airway inﬂammation predominantly
in animal models (3), chitotriosidase
activity is increased in the airways of
smokers and subjects with chronic
obstructive pulmonary disease (COPD)
compared with healthy control subjects
(4, 5), as well as in the serum of patients
with asthma (6). YKL-40 levels are
increased in the serum and lungs of patients
with asthma compared with healthy
control subjects, and they correlate with
markers of disease severity (7, 8).
However, information is still lacking
regarding the suitability of these proteins as
biomarkers of airway inﬂammation. It was
therefore our aim in this study to provide a
more detailed evaluation of serum chitinase
levels in airway disease by investigating both
serum YKL-40 levels and chitotriosidase
activity in parallel in patients taking part
in the European multicenter BIOAIR
(Longitudinal Assessment of Clinical Course
and Biomarkers in Severe Chronic Airway
Disease) study (9–11). The design of this
study enabled us, for the ﬁrst time, to
examine in the same study the repeatability
of chitinase measurements over a 1-year
period, the effect of oral steroid treatment,
and the effect of spontaneous exacerbations
in both patients with asthma and
patients with COPD. YKL-40 levels and
chitotriosidase activity are subject to genetic
regulation and were therefore also analyzed,
taking into account the effect of common
polymorphisms in the CHI3L1 and CHIT1
genes, respectively. CHI3L1 rs4950928
(2131C.G) has been associated with
features of asthma and increased serum
YKL-40 (8, 12), and individuals homozygous
for a relatively common 24-bp duplication in
exon 10 of CHIT1 (rs3831317) display a
complete lack of chitotriosidase activity (13).
To assess whether acute airway obstruction
and inﬂammation affect chitinase levels in
blood or sputum, we also examined the effect
of inhaled allergen on YKL-40 levels in two
separate subsets of patients with mild atopic
asthma following high-dose or repeated low-
dose allergen challenge. Some of the results
of these studies have been reported
previously in the form of abstracts (14–16).
Methods
Subjects
BIOAIR cohort. BIOAIR is a European
multicenter study (9–11). Brieﬂy, subjects
were between 18 and 80 years of age and
were divided into three groups: patients
with mild to moderate asthma, patients
with severe asthma, and patients with
COPD (Table 1). Further details and
deﬁnitions regarding the BIOAIR study and
patient groups are provided in the online
supplement. To examine the repeatability
of biomarker measurements, patients
attended up to six scheduled clinic visits
over the 1-year study period. Patients who
had exacerbations had additional visits.
Most patients taking part in the BIOAIR
study (88% of all subjects) underwent a
2-week, double-blind, placebo-controlled
oral steroid intervention consisting of a
standard course of prednisolone (0.5 mg/kg
body weight/d) added to regular treatment.
For certain comparisons, a positive
response to therapy was deﬁned as an
increase in FEV1 greater than 12%
following steroid treatment.
Healthy subjects. Baseline chitinase
measurements were obtained from a group
of up to 72 healthy volunteers aged 21–77
years (average age, 40 yr) recruited at the
Academic Medical Center, University of
Amsterdam, who have been examined in
previous studies of chitinase levels (17).
Allergen-challenged subjects with
asthma. Plasma and sputum samples were
collected from well-characterized patients
with mild atopic asthma taking part in two
separate allergen challenge studies (see
online supplement for details). Patients
underwent either (1) high-dose allergen
challenge (n = 16) to produce a 20% acute
fall in FEV1 (18) or (2) repeated low-dose
allergen challenge (n = 15) leading to
minimal bronchoconstriction but
eosinophilic airway inﬂammation and
increased bronchial hyperresponsiveness to
methacholine (19).
Clinical Measurements
Lung function measurements, reversibility
testing, fraction of exhaled nitric oxide
(FENO) measurements, skin prick testing,
and sputum induction and processing were
all performed as described in the online
supplement. Serum periostin levels were
measured by ELISA using two rat
antihuman periostin monoclonal antibodies
(clones SS18A and SS17B) as described
previously (20).
YKL-40 assay. Serum YKL-40 levels
were measured by ELISA according to
the manufacturer’s instructions (Human
Chitinase 3-like 1 DuoSet ELISA
Development Kit; R&D Systems, Abingdon,
UK). Two different dilutions were made for
each sample, from which an average was
obtained. All samples were analyzed in
duplicate in random order. Within-assay
variability was 3%, and between-assay
variability was 14%.
Chitotriosidase assay. Chitotriosidase
activity in the serum was detected
ﬂuorometrically using the substrate
4-methylumbelliferyl-(4-deoxy)chitobiose
as described elsewhere (21, 22) and as
outlined in more detail in the online
supplement. To discriminate between
chitotriosidase activity and that of AMCase
in serum samples, a neutralizing antibody
against AMCase was used.
At a Glance Commentary
Scientiﬁc Knowledge on the
Subject: The chitinases and related
proteins have shown promise as novel
circulating markers of inﬂammation in
patients with respiratory disease.
What This Study Adds to the
Field: We contribute knowledge to
this ﬁeld regarding factors that regulate
levels of chitinases and related proteins
in the blood. We conclude that these
proteins are relatively steroid-
insensitive, non–T-helper cell type 2–
speciﬁc markers of chronic rather than
acute disease processes.
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Genotyping
The CHIT1 24-bp duplication (rs3831317)
and 2131C.G polymorphism in the
CHI3L1 gene (rs4950928) were genotyped
as described in the online supplement.
DNA was available from subjects taking
part in the BIOAIR study (n=179), as well
as from the healthy control subjects (n=58
for CHI3L1 and n=72 for CHIT1).
Statistics
Basic comparisons were performed using
GraphPad Prism statistical software
(GraphPad Software, La Jolla, CA), and
P values ,0.05 were accepted as signiﬁcant.
The majority of variables in this study were
not normally distributed according to the
Kolmogorov-Smirnov test and therefore
were analyzed using nonparametric tests.
The results are presented as median
(interquartile range) unless otherwise
stated. Further analyses were performed
using Stata 13 software (StataCorp, College
Station, TX). Linear regression was used to
adjust for age, sex, and genotype, and a linear
mixed model was used for dependent
samples (e.g., before vs. after treatment). For
all regression analyses, logarithmic
transformations of chitinase and YKL-40
measurements were performed before analysis.
Fisher’s exact test was used to examine
genotype frequencies between groups.
Multiple regression models were constructed
to examine the effects of age, sex, genotype,
smoking, disease, and lung function on
chitinase levels. Some variables showed clear
deviations from linearity, and these were ﬁtted
using cubic splines with three knots (23).
Results
Baseline Serum YKL-40 Levels and
Chitotriosidase Activity
The results are presented as median
(interquartile range). Compared with serum
YKL-40 levels in healthy control subjects
(23.0 [17.1–26.5] ng/ml; n = 48), levels were
signiﬁcantly elevated in patients with mild to
moderate asthma (33.3 [22.9–43.5] ng/ml;
n = 61; P, 0.001) and those with severe
asthma (43.3 [31.1–75.9] ng/ml; n = 76;
P, 0.001) and were highest in patients
with COPD (64.0 [37.4–142.2] ng/ml;
n = 45; P, 0.001) (Figure 1A). All
patient groups were signiﬁcantly
different compared with each other
(mild to moderate asthma vs. severe asthma,
P = 0.002; mild to moderate asthma vs.
COPD, P, 0.001; severe asthma vs. COPD,
P = 0.006).
Compared with healthy control
subjects (62.5 [46.0–90.0] nmol/ml/h;
n = 72), serum chitotriosidase activity was
greatest in patients with COPD (169.5
[90.0–269.6] nmol/ml/h; n = 52; P, 0.001)
but was also signiﬁcantly elevated in
subjects with mild to moderate asthma
(96.3 [61.3–137.6] nmol/ml/h; n = 63; P,
Table 1. Baseline Subject Characteristics (BIOAIR Study)
Mild to Moderate
Asthma Severe Asthma COPD P Value
Total number of patients included 76 93 64 ND
Age, yr, mean6 SD (min–max) 43.46 1.6 (21–70) 50.26 1.4 (18–72) 64.36 1.1 (47–79) ,0.0001*
Females, % 59.7 57.1 22.6 ,0.0001†
FEV1, % predicted 89.96 2.5 73.26 2.3 48.046 1.9 ,0.0001*
FEV1, L 2.766 0.09 2.086 0.08 1.406 0.08 ,0.0001*
FEV1/FVC 0.706 0.01 0.676 0.01 0.516 0.01 ,0.0001
†
Reversibility, DFEV1 % predicted 10.56 0.7 8.76 0.7 3.46 0.5 ,0.0001
†
ICS (beclomethasone equivalent), mg,
median (mean6SD)
775 (6066 223) 1,600 (2,0446 912) 800 (1,0626 631) ,0.0001†
OCS (prednisolone equivalent),‡ mg,
median (mean6SD)
— 10 (14.156 11.8) ND
BMI, kg/m2 25.26 0.5 28.36 0.6 27.36 0.7 0.0004x
St. George’s Respiratory Questionnaire
score
23.26 2.2 44.86 2.1 44.56 2.3 ,0.0001x
Asthma Control Questionnaire score 1.036 0.7 2.036 0.1 — ,0.0001║
CRP, mg/L 4.66 1.2 5.66 0.8 10.46 2.2 0.01†
Atopy, % 46.9 37.6 —¶ 1.0**
FENO, ppb 39.36 4.4 46.96 6.6 17.06 2.9 0.002*
Serum periostin, ng/ml 86.06 25.75 93.56 45.21 80.16 24.02 0.05†
Sputum eosinophils, % 5.96 1.8 17.96 3.7 3.36 1.7 0.001*
Sputum neutrophils, % 45.86 4.4 40.46 3.8 62.76 5.1 0.004†
Blood eosinophils, 108/L 3.206 0.4 3.756 0.4 2.726 0.4 0.22
Blood neutrophils, 109/L 3.786 0.15 5.436 0.29 5.036 0.23 ,0.0001x
Definition of abbreviations: BIOAIR = Longitudinal Assessment of Clinical Course and Biomarkers in Severe Chronic Airway Disease; BMI = body mass
index; COPD = chronic obstructive pulmonary disease; CRP =C-reactive protein; FENO = fraction of exhaled nitric oxide; ICS = inhaled corticosteroids;
ND = not determined; OCS = oral corticosteroids.
Data are mean6 SD unless otherwise noted.
*Three-way comparison significant; all groups are different.
†Significant difference between patients with severe asthma and those with COPD.
‡One patient with COPD received 60 mg/d of prednisolone.
xSignificant difference between patients with severe and those with mild to moderate asthma.
║Mann-Whitney U test.
¶Atopy was an exclusion criterion for the COPD group.
**x2 test.
ORIGINAL ARTICLE
James, Reinius, Verhoek, et al.: Chitinases Are Increased in COPD and Asthma 133
0.001) and those with severe asthma (90.7
[58.1–134.8] nmol/ml/h; n = 84; P = 0.001)
(Figure 1B). Chitotriosidase levels in both
asthma groups were lower than those in
patients with COPD (P, 0.001).
Effect of CHI3L1 rs4950928 and CHIT1
rs3831317 Genotype on YKL-40
Levels and Chitotriosidase Activity
The frequencies of the CHIT1 rs3831317 and
CHI3L1 rs4950928 genotypes in the different
subject groups are shown in Table 2. The
occurrence of the different genotypes was
not different between the subject groups
(P = 0.976 for CHI3L1 rs4950928 and
P = 0.421 for CHIT1 rs3831317).
YKL-40 levels were related to CHI3L1
rs4950928 genotype (Figure 2A). When all
subjects were analyzed together, those with
the CC genotype showed higher levels of
serum YKL-40 (39.0 [25.5–75.5] ng/ml;
n = 120) than those with the CG genotype
(32.2 [20.2–47.5] ng/ml; n = 54; P = 0.009)
and those with the GG genotype, in whom
levels were lowest (18.1 [11.5–28.3] ng/ml;
n = 11; P, 0.001).
Following regression analyses with
adjustment for CHI3L1 rs4950928
genotype, age, and sex, patients with mild
and severe asthma and patients with COPD
all still had signiﬁcantly higher YKL-40
levels than healthy control subjects (P,
0.001). A signiﬁcant difference also
remained between patients with mild
asthma and those with COPD (P = 0.018),
but not between patients with mild asthma
and those with severe asthma (P = 0.062) or
between patients with severe asthma and
those with COPD (P = 0.283).
Serum chitotriosidase activity showed a
strong relationship with CHIT1 rs3831317
genotype (Figure 2B). Subjects homozygous
for a 24-bp duplication in exon 10 were
completely lacking in chitotriosidase
activity, although this genotype was rare
among subjects (2.3% in total) and
therefore the data were too few to be
included in statistical comparisons.
Comparing all subjects, those lacking the
24-bp duplication had signiﬁcantly greater
levels of chitotriosidase than heterozygotes
(respectively, 113.6 [74.5–156.6] [n = 146]
vs. 59.2 [36.0–86.2] nmol/ml/h
[n = 76]; P, 0.0001).
When between-group differences in
chitotriosidase activity were examined in
regression analyses with adjustment for age,
sex, and genotype, mild asthma and COPD
were signiﬁcantly different compared with
healthy control subjects (P, 0.001), whereas
severe asthma was not (P = 0.106). There were
also signiﬁcant differences in chitotriosidase
activity between COPD and severe asthma
(P = 0.007) and between mild and severe
asthma (P = 0.051), but not between mild
asthma and COPD (P = 0.416).
Overall, there were no associations
between CHI3L1 rs4950928 or CHIT1
rs3831317 genotype and subject
characteristics (see Tables E4 and E5 in the
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Figure 1. Serum levels of YKL-40 and chitotriosidase activity. (A) YKL-40 levels are shown in healthy
control subjects and patients with mild to moderate or severe asthma and patients with chronic
obstructive pulmonary disease (COPD). (B) Chitotriosidase activity is shown in healthy control
subjects, patients with mild to moderate or severe asthma, and patients with COPD. P values are
shown for comparisons with healthy control subjects. The results are presented as individual data
points with median bars.
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online supplement), apart from lower
periostin levels in patients with asthma with
the rs4950928 GG genotype (CC = 88
[71–109] ng/ml; CG = 83 [67.8–102.3] ng/ml;
GG = 57.5 [50.3–68.8] ng/ml; P = 0.003) and
a higher body mass index (BMI) in patients
with asthma lacking the 24-bp duplication at
rs3831317, or wild type, compared to those
heterozygous for the duplication (wild type =
27 [24–30] kg/m2; heterozygous = 26 [23–27]
kg/m2; P = 0.034). However, it should also be
noted that the present study is underpowered
to examine clinical characteristics between
different genotypes in the resulting
subgroups.
Relationships between the Chitinases
and Subject Characteristics
Possible correlations between levels of
serum YKL-40 and chitotriosidase activity
and subject characteristics were examined
(Table 3). In all BIOAIR patients, age was
found to correlate positively with both
YKL-40 (r = 0.49; P, 0.001) and
chitotriosidase activity (r = 0.47; P, 0.001).
Measures of lung function showed negative
correlations with both YKL-40 levels
(FEV1 % predicted, r =20.42, P, 0.0001;
FVC % predicted, r = 20.40, P, 0.0001;
FEV1/FVC, r =20.34, P, 0.001) and
chitotriosidase levels (FEV1, r =20.25, P,
0.001; FVC, r =20.16, P = 0.03; FEV1/FVC,
r =20.23, P = 0.001). In addition, there was
a weak but statistically signiﬁcant correlation
between serum YKL-40 level and
chitotriosidase activity (r = 0.221; P = 0.003).
Correlations in the separate subject groups
are shown in Tables E6 and E7. YKL-40 also
showed a weak though signiﬁcant
association with BMI, but only in patients
with asthma (r = 0.21; P = 0.01).
Chitinase Levels in T-Helper Cell Type
2–driven Asthma
In patients with asthma, no signiﬁcant
correlations were observed between either
YKL-40 level or chitotriosidase activity
and proposed markers of T-helper cell type
2 (Th2)-type inﬂammation, including
serum periostin, blood eosinophils, FENO,
and total IgE (Table E6). To further
examine possible relationships between
chitinase levels and Th2-type inﬂammation,
patients with asthma were divided into a
Th2-high group, based on the presence of
both blood eosinophil counts and periostin
levels above the group median (median
eosinophil count, 0.253 109/L; median
periostin level, 84 ng/ml), and a Th2-low
group, in whom levels of both biomarkers
were below the median (Table 4). No
differences in chitinase levels were observed
between the Th2-low and Th2-high groups.
Effect of Steroid Treatment on
Chitinase Levels
The effect of a 2-week, placebo-controlled
oral steroid intervention was examined in
subjects taking part in the BIOAIR study.
No signiﬁcant reductions in YKL-40 levels
were observed following corticosteroid
treatment (Figure 3A).
When the effect of steroid treatment
was analyzed in all patient groups, serum
chitotriosidase activity was slightly reduced
following treatment with oral prednisolone
(106 [66–168] vs. 101 [63–143] nmol/ml/h;
n = 157; P, 0.001). However, when patient
groups were analyzed separately
(Figure 3B), oral steroid treatment caused a
reduction in chitotriosidase activity only in
patients with COPD (186 [111–279] vs. 128
(86–189) nmol/ml/h; n = 38; P, 0.001).
When interactions between treatment and
age were taken into account, the interaction
between treatment and subject groups
ceased to be signiﬁcant. The interaction
between treatment and age in this model
was negative (P = 0.001); that is, the
reduction in chitotriosidase activity was
greater in older people. There were no
interactions between the examined
genotypes and effect of corticosteroid
therapy on chitinase levels.
In patients with asthma, neither
baseline YKL-40 level nor chitotriosidase
activity was associated with response to
corticosteroid therapy, deﬁned as an
increase in FEV1 greater than 12% following
treatment with oral prednisolone. YKL-40
levels in nonresponders were 39 (26–69)
ng/ml (n = 102) compared with 33 (25–53)
ng/ml in responders (n = 22) (P = 0.276),
whereas chitotriosidase activity was 94
(61–132) nmol/ml/h in nonresponders
compared with 94 (60–158) nmol/ml/h in
responders (P = 0.594).
Effect of Exacerbations on Chitinase
Levels
Compared with baseline, neither YKL-40
level nor chitotriosidase activity was
signiﬁcantly different during exacerbations
(Table E8). Exacerbations occurred in 7
patients with mild to moderate asthma, 27
patients with severe asthma, and 11 patients
with COPD. Chitinase levels before and
during exacerbations showed no signiﬁcant
interactions with age or genotype.
Repeatability of Chitinase
Measurements
In the BIOAIR study, patients were followed
for 1 year, during which time up to six blood
samples were obtained at different time
points (not during exacerbations). The data
for average between-visit variability for
YKL-40 levels and serum chitotriosidase
activity, as well as the variability of FENO and
percentage of sputum eosinophils for
comparison, are shown in Table 5.
Chitinase Levels and Smoking Status
Of 76 patients with mild asthma, 1 was a
current smoker and 14 were former
smokers. Of 93 patients with severe asthma,
29 were former smokers and 2 were current
Table 2. Frequencies of CHI3L1 rs4950928 and CHIT1 rs3831317 Genotypes
CHI3L1 rs4950928 CC CG GG
Mild to moderate asthma (n = 49) 61.2 30.6 8.2
Severe asthma (n = 62) 63.0 30.6 6.4
COPD (n = 40) 67.5 27.5 5
Healthy control subjects (n = 57) 70.2 24.5 5.3
CHIT1 rs3831317
No 24-bp
Duplication Heterozygous Homozygous
Mild to moderate asthma (n = 58) 65.5 31.0 3.5
Severe asthma (n = 72) 63.9 34.7 1.4
COPD (n = 49) 67.3 28.6 4.1
Healthy control subjects (n = 64) 60.9 39.1 0
Definition of abbreviation: COPD = chronic obstructive pulmonary disease.
Results are presented as percentages.
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smokers. All 64 patients with COPD were
either former (n = 45) or current (n = 19)
smokers. We found no signiﬁcant
differences in either YKL-40 or
chitotriosidase levels when we compared
the patients with asthma who were never
smokers with those who had smoked
previously, nor did we ﬁnd such differences
when we compared patients with COPD
who were former versus current smokers
(Figure E2). When univariate correlations
were performed on the BIOAIR group as
a whole, a signiﬁcant relationship with
number of pack-years smoked was
observed (Table 3), although this
association was not apparent when the
disease groups were analyzed separately
(Tables E6 and E7).
Multiple Regression Analyses
As the ﬁndings above implied that YKL-40
levels and chitotriosidase activity are
affected by several factors, we performed
multiple regression analyses to examine the
effects of the independent variables age, sex,
genotype, smoking status, disease group,
and lung function on chitinase levels.
In the BIOAIR patient group as a
whole, YKL-40 levels were signiﬁcantly
associated with, in descending order of
importance, lung function (FVC %
predicted), rs4950928 genotype, age, and sex
(Tables 6 and 7). FVC showed a nonlinear
relationship with YKL-40 levels, as
demonstrated in Figure E3. For the whole
patient group model, smoking (in pack-
years) and disease group were without
signiﬁcant effects. Multiple regression
analyses in the separate groups are shown
in Tables E9–E11. Generally similar
associations were observed when the groups
were analyzed separately, although there
was no effect of lung function in patients
with mild asthma (Table E9).
In descending order of importance in
the BIOAIR group as a whole, genotype,
age, and smoking status (in pack-years)
were found to have signiﬁcant effects on
chitotriosidase activity. The difference
between mild asthma and COPD was
signiﬁcant, but the difference between mild
and severe asthma was not. No signiﬁcant
relationships with lung function were
observed (Tables 6 and 7). The
relationship between chitotriosidase
activity and number of pack-years of
smoking was not linear, as shown in
Figure E4. When the patient groups were
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Figure 2. Serum levels of YKL-40 and chitotriosidase activity according to CHI3L1 rs4950928 and CHIT1
rs3831317 genotype. (A) YKL-40 levels and (B) chitotriosidase activity are shown in the different subject
groups according to relevant genotype. YKL-40 is shown in subjects with the rs49509282131 CC, CG, and
GG genotypes. Information regarding CHI3L1 genotype and YKL-40 levels was available for 39 healthy
control subjects and 49 subjects with mild to moderate asthma, 60 with severe asthma, and 37 with chronic
obstructive pulmonary disease (COPD). Chitotriosidase activity is shown in subjects lacking a 24-bp
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analyzed separately (Tables E9–E11),
we found that the factors affecting
chitotriosidase activity were age and
genotype. A relationship with pack-years
of smoking was observed only in patients
with mild asthma, in whom it should be
noted that the number of patients with
a positive smoking history was also
relatively low (15 of 76).
Effect of Allergen Challenge on
YKL-40 Levels
The effects of high-dose and repeated low-dose
allergen challenges on plasma and sputum
YKL-40 levels were examined in patients with
mild atopic asthma (Figure 4). Plasma YKL-40
was not affected by either high-dose allergen
challenge or repeated low-dose allergen
challenge, although both challenges resulted
in signiﬁcant physiological responses
(i.e., reductions in FEV1 and increased
responsiveness toward inhaled methacholine)
(18, 19). Sputum YKL-40 levels were
signiﬁcantly higher following high-dose
allergen challenge (before challenge, 68
[48–96] ng/g sputum; after challenge, 113
[69–258] ng/g sputum; n = 15; P = 0.007), but
they were not affected by repeated low-dose
allergen challenge. Sputum YKL-40 levels
correlated with number of sputum
neutrophils in both studies (r= 0.5; P, 0.05).
Discussion
The main ﬁndings of the present study are
that serum YKL-40 levels and chitotriosidase
activity are elevated in patients with asthma
and in patients with COPD compared with
healthy control subjects. Both YKL-40 and
chitotriosidase were higher in subjects with
COPD than in patients with mild to
moderate asthma or those with severe
asthma, and the increased levels correlated
with reduced lung function and were
relatively steroid insensitive.We demonstrate
that genetic variability and age strongly affect
both YKL-40 and chitotriosidase activity but
that the increased levels compared with
healthy control subjectsmostly persisted after
adjustment for these factors. Acute changes
in airway inﬂammation caused by allergen
exposure or naturally occurring
exacerbations were without effect on the
circulating chitinases measured, and the
variability of serum YKL-40 and
chitotriosidase activity over time was
relatively low. Taken together, these ﬁndings
conﬁrm that the chitinases represent a
distinct class of biomarkers of severe airway
disease and provide important information
regarding their use as such.
Serum YKL-40 levels and chitotriosidase
activity have not previously been examined in
parallel in patients with COPD and patients
with asthma. The ﬁnding of increased serum
YKL-40 in patients with asthma conﬁrms
previous observations (7, 8, 24, 25). The
higher levels in patients with severe asthma
than in patients with mild asthma, along with
the correlation between YKL-40 and reduced
lung function, strengthen the association of
serum YKL-40 with disease severity (7, 8).
The exact biological role of YKL-40 remains
unclear, but it consistently correlates with
airway obstruction in studies of patients
with asthma (7, 8, 24). YKL-40 associates
with measures of airway remodeling, such as
bronchial wall thickness and subepithelial
Figure 2. (Continued). duplication in exon 10 of CHIT1 rs3831317 (wild type), those heterozygous for the 24-bp duplication, and those homozygous for the 24-bp
duplication. Information regarding CHIT1 genotype and chitotriosidase activity were available from 64 healthy control subjects and 51 patients with mild to moderate
asthma, 67 with severe asthma, and 44 with COPD. The results are presented as individual data points with median bars. *P,0.05, **P,0.01, ***P,0.001.
Table 3. Correlations between Subject Characteristics and Chitinase Levels in BIOAIR Subjects
Subject Characteristic
YKL-40 (ng/ml) Chitotriosidase Activity (nmol/ml/h)
Spearman’s Rank Correlation
Coefﬁcient P Value
Spearman’s Rank Correlation
Coefﬁcient P Value
Age, yr 0.49 ,0.0001 0.47 ,0.0001
BMI, kg/m2 0.13 0.08 0.02 0.80
FEV1, L 20.41 ,0.0001 20.25 ,0.001
FEV1, % predicted 20.42 ,0.0001 20.17 0.02
FEV1/FVC 20.34 ,0.0001 20.23 0.001
FVC, L 20.31 ,0.0001 20.16 0.03
FVC, % predicted 20.40 ,0.0001 20.07 0.33
Reversibility, DFEV1 % predicted 20.20 0.01 20.19 0.01
ICS, mg/d 0.12 0.11 20.05 0.51
St. George’s Respiratory Questionnaire
score
0.21 0.01 0.04 0.58
Asthma Control Questionnaire score 0.22 0.01 0.03 0.74
Periostin, ng/ml 0.12 0.11 20.04 0.59
Smoking, pack-years 0.32 ,0.001 0.34 ,0.001
FENO, ppb 20.05 0.68 20.08 0.42
CRP, mg/L 0.17 0.04 0.08 0.33
IgE, kU/L 20.05 0.51 20.10 0.16
Sputum eosinophils, % 20.15 0.16 0.05 0.62
Sputum neutrophils, % 0.16 0.14 0.15 0.13
Sputum macrophages, % 20.15 0.11 20.16 0.06
Blood eosinophils, 109/L 20.15 0.05 20.05 0.54
Blood neutrophils, 109/L 0.08 0.28 0.11 0.16
Definition of abbreviations: BIOAIR = Longitudinal Assessment of Clinical Course and Biomarkers in Severe Chronic Airway Disease; BMI = body mass
index; CRP =C-reactive protein; FENO = fraction of exhaled nitric oxide; ICS = inhaled corticosteroids.
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ﬁbrosis (7, 8), which is in line with reports
that YKL-40 increases the proliferation of
bronchial smooth muscle cells (26, 27) and is
involved in ﬁbrotic lung diseases (28). Also of
relevance to a role in airway remodeling
is the discovery that a high serum YKL-40
level is associated with a greater decline in
lung function over time (29). The increased
YKL-40 levels in patients with COPD
compared with patients with asthma may
therefore reﬂect a greater degree of airway
remodeling.
It is widely recognized that asthma is a
heterogeneous disorder of multiple
phenotypes characterized by differing
clinical characteristics and underlying
pathobiology. Patients with Th2-driven
asthma have been described as being more
atopic and more sensitive to corticosteroid
therapy and as having more airway
eosinophils and a greater degree of
bronchial hyperresponsiveness (30). Blood
eosinophils, FENO, and serum periostin
levels have been described as potential
biomarkers of Th2-type airway
inﬂammation (30). In the present study, we
did not observe any relationships between
either YKL-40 or chitotriosidase with atopic
status, response to corticosteroid therapy,
blood eosinophil numbers, or serum
periostin levels. Dividing patients into
Th2-high and Th2-low groups based on
having both high blood eosinophil and high
periostin levels did not reveal any
differences in chitinase levels.
In accordance with our ﬁndings, Jia and
colleagues showed that whereas periostin
may be the most sensitive and speciﬁc
indicator of airway eosinophilia, there were
no correlations between YKL-40 with
periostin, eosinophils (in blood, sputum, or
tissue), or FENO (31). Regarding atopy, the
reported ﬁndings are variable. On one hand,
Chupp and colleagues (7) and Ober and
coworkers (12) reported no associations
between YKL-40 with atopy or IgE. On the
other hand, Tang and colleagues (24) found
higher circulating YKL-40 levels in Chinese
patients with higher IgE levels, and
Specjalski and coworkers (32) made the
same observation in patients with atopic
versus nonatopic asthma. In the present
study, we also observed the highest levels of
YKL-40 and chitotriosidase in patients with
COPD, further suggesting that the chitinases
are not Th2-speciﬁc markers of airway
disease. Interestingly, a weak association
with increased BMI was observed, which has
also been described previously (32). In
contrast to our ﬁndings, initial studies in
mice did suggest an involvement in Th2-
type processes, as the expression of chitinase
proteins (AMCase, Ym1, and Ym2) is
dependent on IL-13 (3, 33, 34) and mice
lacking Brp39 (YKL-40) have defective
IL-13–induced inﬂammation (35).
Chitotriosidase activity was
signiﬁcantly elevated in patients with mild
to moderate asthma compared with healthy
control subjects, but not in patients with
severe asthma, following adjustment for age,
sex, and genotype. Published reports
regarding chitotriosidase activity in asthma
are few and varied, with differences based
on the matrix studied, the severity of
patients’ disease, and/or patients’ current
medications. Studies have shown that,
compared with healthy control subjects,
there may be reduced chitotriosidase
activity in bronchoalveolar lavage (BAL)
ﬂuid from patients with mild asthma not
being treated with steroids (4), no
difference in serum from patients with
asthma (36), and increased levels in the
serum of patients with asthma with or
without allergies (6). The lack of association
with disease severity, alongside conﬂicting
previous ﬁndings, suggests that the
involvement of chitotriosidase in asthma is
less clear than that of YKL-40.
The increased YKL-40 and
chitotriosidase seen in patients with COPD
is in accordance with previous observations.
Increased BAL chitotriosidase activity has
been found in smokers (4, 5), and elevated
circulating YKL-40 has been found in
patients with COPD compared with control
subjects, in whom levels may relate to
smoking history (37, 38). In the present
study, no differences were observed
between current smokers and ex-smokers,
suggesting that current smoke exposure per
se is not responsible for increased chitinase
levels. However, a signiﬁcant relationship
between chitotriosidase activity and pack-
years of smoking was observed in the
multiple regression analyses, suggesting
that the degree of airway damage may affect
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Figure 3. Effect of oral corticosteroid treatment
on serum chitotriosidase activity and YKL-40
levels. (A) Serum YKL-40 levels and (B)
chitotriosidase activity were measured before
and after 2 weeks of treatment with oral
prednisolone. The results are presented as
median values (with interquartile range) for
patients with chronic obstructive pulmonary
disease (COPD), severe asthma, and mild to
moderate asthma. Paired comparisons were
possible for 55 (YKL-40) and 53 (chitotriosidase)
patients with mild to moderate asthma, 67
(YKL-40) and 66 (chitotriosidase) patients with
severe asthma, and 38 patients with COPD.
***P, 0.001 compared with presteroid values.
Table 4. YKL-40 Levels and Chitotriosidase Activity in Th2-Low and Th2-High Patients with Asthma
Th2-Low Th2-High P Value
YKL-40, ng/ml 36.9 (21.9–53.4) (n = 43) 36.5 (25.5–55.6) (n = 46) 0.49
Chitotriosidase activity, nmol/ml/h 84.7 (56.5–122.8) (n = 47) 96.6 (56.0–156.9) (n = 48) 0.19
Definition of abbreviation: Th2 = T-helper cell type 2.
Asthma patients were grouped according to having both serum periostin levels and blood eosinophil numbers above (Th2-high) or below (Th2-low) the
group median (median eosinophil count, 0.253 109/L; median periostin level, 84 ng/ml). Results are presented as median (interquartile range).
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chitotriosidase activity. There may be
involvement of airway neutrophils and
macrophages, as these were more abundant
in COPD sputum compared with asthma
sputum. Both neutrophils and macrophages
are known sources of YKL-40 and
chitotriosidase (39–41), although no
obvious relationships were observed
between airway neutrophils and
macrophages and either YKL-40 or
chitotriosidase in BIOAIR study patients.
We and others have demonstrated
that serum levels of both YKL-40 and
chitotriosidase increase with age (42, 43). The
patient groups in the BIOAIR study were not
age matched, but signiﬁcant between-group
differences remained following statistical
adjustment for age, suggesting that age alone
is not responsible for any of the observed
increases in chitinase levels.
YKL-40 and chitotriosidase levels were
both strongly affected by variations in the
CHI3L1 and CHIT1 genes, respectively.
Genetic variants in the CHI3L1 gene have
been associated with asthma and related
phenotypes (12, 44–46). Ober and colleagues
(12) observed a relationship between one
particular CHI3L1 polymorphism (2131C.G
rs4950928), circulating YKL-40 levels, and
asthma. We conﬁrm that the rs4950928 CC
genotype was associated with greater levels
of circulating YKL-40; in contrast to Ober
and colleagues, however, we did not observe
any associations with markers of asthma
severity, which has also been the case in
other recent investigations (46). As DNA
methylation can affect transcription factor
binding, we investigated the effect of
DNA methylation at three sites located in
the CHI3L1 promoter region near
rs4950928 because this single-nucleotide
polymorphism affects MYC and MAX
binding (12). However, no clear trends were
observed between DNA methylation in this
region and circulating YKL-40 levels
(Figure E1 and Table E3). The CHIT1
24-bp duplication (rs3831317) results in a
nonfunctional protein lacking enzymatic
activity (13). This genetic variant shows no
association with asthma and atopy (47, 48),
and in the present study no differences in
the frequencies of the CHIT1 rs3831317
variants were observed in the different
disease groups.
The BIOAIR study included a 2-week,
placebo-controlled steroid intervention
with oral prednisolone. In patients with
asthma, steroid treatment did not reduce
serum YKL-40 or chitotriosidase activity.
There was a reduction in serum
chitotriosidase activity, but not of YKL-40,
after steroid treatment in patients with
COPD, those who were oldest, and those
who had the highest levels of chitotriosidase
activity. It should be noted, however, that
subjects in the BIOAIR study used inhaled
corticosteroids. That could potentially have
affected basal chitinase levels, as Lai and
colleagues recently showed that serum
YKL-40 was reduced following 8 weeks of
inhaled corticosteroid treatment (49).
Nevertheless, as we and others have shown,
patients taking the highest doses of ICS
are also those with the highest levels of
YKL-40, suggesting that YKL-40 release is
relatively refractory to steroid treatment
(7, 49). One may speculate that the reason why
chitinase levels are highest in patients with the
most severe disease and taking the highest
levels of corticosteroids is that corticosteroids
are able to alternatively activate macrophages,
a cell type known to release mediators involved
in tissue repair (50).
To investigate the repeatability of
chitinase measurements, up to six serum
samples were collected from the same
patients over a 1-year period. The mean
coefﬁcients of variation were 16–19% for
chitotriosidase and 32–38% for YKL-40.
In comparison with other biomarkers
measured at the same time points, such as
FENO (coefﬁcient of variation, 45–56%) and
sputum eosinophil percentage (coefﬁcient
Table 6. Multiple Regression Analyses in BIOAIR Patients
b (95% CI) P Value Adjusted R2
YKL-40, n = 140
Age 0.017 (0.009–0.025) ,0.001
FVC, % predicted, spline 1 20.032 (20.044 to 20.021) ,0.001
FVC, % predicted, spline 2 0.021 (0.010–0.032) ,0.001
CHI3L1 rs4950928, CC vs. CG 20.457 (20.668 to 20.246) ,0.001
CHI3L1 rs4950928, CC vs. GG 20.959 (21.360 to 20.558) ,0.001
Sex 20.331 (20.541 to 20.120) 0.002
Smoking pack-years 20.003 (20.012 to 0.005) 0.419
Group, MA vs. SA 0.046 (20.211 to 0.303) 0.725
Group, MA vs. COPD 0.136 (20.330 to 0.601) 0.566
Combined model 0.512
Chitotriosidase, n = 152
Age 0.019 (0.012–0.025) ,0.001
CHIT1 rs3831317, WT vs. HET 20.746 (20.925 to 20.567) ,0.001
Pack-years, spline 1 0.042 (0.015–0.068) 0.002
Pack-years, spline 2 20.066 (20.111 to 20.021) 0.005
Group, MA vs. COPD 20.569 (21.080 to 20.057) 0.030
Group, MA vs. SA 20.147 (20.359 to 0.065) 0.174
Sex 20.084 (20.260 to 0.092) 0.347
FVC, % predicted 0.002 (20.002 to 0.007) 0.301
Combined model 0.473
Definition of abbreviations: BIOAIR = Longitudinal Assessment of Clinical Course and Biomarkers
in Severe Chronic Airway Disease; CI = confidence interval; COPD = chronic obstructive
pulmonary disease; HET = heterozygous for 24-bp duplication at rs3831317; MA =mild to
moderate asthma; SA = severe asthma; WT =wild type lacking 24-bp duplication at rs3831317.
Table 5. Biomarker Stability in the BIOAIR Study
Mild to Moderate Asthma Severe Asthma COPD
Chitotriosidase activity 19 16 17
YKL-40 32 36 38
FENO 45 46 52
Sputum eosinophil percentage 95 91 106
Definition of abbreviations: BIOAIR = Longitudinal Assessment of Clinical Course and Biomarkers in
Severe Chronic Airway Disease; COPD= chronic obstructive pulmonary disease; FENO = fraction of
exhaled nitric oxide.
Data represent average between-visit coefficient of variation (as a percentage) of up to six repeat visits.
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of variation, 91–95%), both chitotriosidase
and YKL-40 were relatively stable.
Naturally occurring exacerbations, most
commonly caused by viral infections, in
patients with severe asthma and patients
with COPD were without effect on the
levels of the chitinases measured, suggesting
that they do not reﬂect acute changes in
airway inﬂammation.
In the present study, circulating
YKL-40 remained unchanged following
high-dose allergen challenge or repeated
low-dose allergen challenge. Sputum YKL-
40 was increased by a high-dose allergen
challenge. Lee and colleagues also showed that
sputum, but not serum, YKL-40 levels
increased at 7 and 24 hours after a single high-
dose allergen challenge (51). Similarly, Gavala
and colleagues found that BAL ﬂuid YKL-40
levels were increased 48 hours after in vivo
segmental high-dose allergen challenge (52).
Taken together, these data seem to show that
sputum (and BAL) may reﬂect a local release
of YKL-40 during allergen-induced
inﬂammation that is not reﬂected in the
blood. A single high dose of allergen may be
considered a greater challenge for the airways
than repeated low doses, and, as the latter is
considered a more realistic model of natural
allergen exposure, YKL-40 levels may
remain relatively stable during such
exposures in everyday life. In both studies,
sputum YKL-40 correlated with neutrophil
numbers, conﬁrming previous reports of
the cellular origin of YKL-40 (41).
As the BIOAIR study was designed to
compare severe asthma and COPD with mild
asthma, the study cohort lacks an internal
healthy control group, which is a limitation. To
compare chitinase levels with those in healthy
subjects, we used a previously described
control group (17). However, clinical
characteristics of relevance to respiratory
disease were not available for these control
subjects, thus preventing their inclusion in
multiple regression analyses. Nevertheless,
performing such analyses for the groups with
respiratory disease only was able to further
highlight the importance of age, genotype,
lung function, and sex on YKL-40 levels and
similarly the effects of age, genotype, and
smoking history on chitotriosidase activity.
In conclusion, we demonstrate that YKL-
40 and chitotriosidase are relatively steroid-
insensitive biomarkers that are distinctly
elevated in well-characterized patients with
asthma and patients with COPD. Taking into
account age and genetic variability, the
chitinases qualify for measurement as part of
new biomarker panels for the assessment of
severe, chronic lung inﬂammation rather than
acute lung inﬂammation. Furthermore, it will
be of interest in future longitudinal studies to
test the prognostic value of monitoring
chitinases as biomarkers of decline in lung
function (29), be it in patients with asthma,
COPD, ﬁbrosis, or infections or in pediatric
conditions such as bronchopulmonary
dysplasia. n
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Figure 4. Plasma and sputum levels of YKL-40 following high-dose and repeated low-dose allergen
challenges. Plasma levels of YKL-40 were measured (A) before, directly after, and 7 hours after high-
dose allergen challenge (n = 16) and (B) before and after a 7-day repeated low-dose allergen
challenge (n = 14). No significant differences were observed. Sputum supernatant levels of YKL-40
were measured (C) before and 6 hours after high-dose allergen challenge (n = 15) and (D) before and
after a 7-day repeated low-dose allergen challenge (n = 11). The results are expressed as nanograms
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sputum YKL-40 (P = 0.018), but low-dose allergen challenge was without effect.
Table 7. Variable Importance of Multiple Regression Analyses in BIOAIR Patients
Variables Conditional importance Unadjusted R2
YKL-40
FVC, % predicted 0.12362347 0.543417
CHI3L1 rs4950928 genotype 0.12105902 0.543417
Age 0.05651369 0.543417
Sex 0.03374412 0.543417
Smoking pack-years 0.00231065 0.543417
Group 0.00118992 0.543417
Chitotriosidase
CHIT1 rs3831317 genotype 0.23784618 0.5007306
Age 0.10398267 0.5007306
Smoking pack-years 0.03569944 0.5007306
Group 0.01845461 0.5007306
FVC, % predicted 0.00375439 0.5007306
Sex 0.00310467 0.5007306
Definition of abbreviation: BIOAIR = Longitudinal Assessment of Clinical Course and Biomarkers in
Severe Chronic Airway Disease.
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